Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635695 | 0.86 | MEN1 (0.66) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL12635924 | 0.86 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL12636626 | 0.84 | L3MBTL1 (0.55) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL12634827 | 0.83 | HTT (0.57) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL12635728 | 0.83 | L3MBTL1 (0.54) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL2016114 | 0.83 | L3MBTL1 (0.54) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL12634804 | 0.81 | LMNA (0.66) | L3MBTL1SMN1; SMN2POLBHPGDRECQL | |
| SCHEMBL28366489 | 0.81 | MAPT (0.70) | L3MBTL1SMN1; SMN2RECQLMEN1KMT2A | |
| SCHEMBL30466612 | 0.81 | MAPT (0.70) | L3MBTL1SMN1; SMN2RECQLMEN1KMT2A | |
| SCHEMBL12635697 | 0.81 | MAPT (0.57) | L3MBTL1SMN1; SMN2POLBTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220096-B2 | Injectable and stable hydrogels with dynamic properties modulated by biocompatible catalysts | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180104348-A1 | INJECTABLE AND STABLE HYDROGELS WITH DYNAMIC PROPERTIES MODULATED BY BIOCOMPATIBLE CATALYSTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220096-B2 | Injectable and stable hydrogels with dynamic properties modulated by biocompatible catalysts | MMP1, F12, CD44 | L3MBTL1 3327/4885SMN1; SMN2 2918/4885POLB 1292/4885 |
| US-20180104348-A1 | INJECTABLE AND STABLE HYDROGELS WITH DYNAMIC PROPERTIES MODULATED BY BIOCOMPATIBLE CATALYSTS | MMP1, F12, CD44 | L3MBTL1 3327/4885SMN1; SMN2 2918/4885POLB 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.